TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026GuruFocus · 3 days ago
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's DiseaseGuruFocus · 4 days ago
Arrowhead Pharmaceuticals Reports Up to 73% CSF Tau Reduction in Early ARO-MAPT StudyMarketBeat · Oct 14, 2026
Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile TestsGlobeNewsWire · Oct 8, 2026
Cerenome Launches CNSide® CSF Molecular Profile TestsGlobeNewsWire · Oct 6, 2026
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in PatientsGuruFocus · Sep 30, 2026The VictoryShares US Discovery Enhanced Volatility Wtd ETF endeavors to match the investment returns of the Nasdaq VictoryUS Small Cap 500 Long/Cash Volatility Weighted Index (known as the "Long/Cash Index"), excluding any charges for fees and expenses. Its distinct Volatility Weighting Methodology incorporates both fundamental criteria and volatility as factors in an attempt to surpass the performance of conventional market capitalization-weighted indexing strategies. The underlying Long/Cash Index actively manages market risk by strategically decreasing its equity market involvement during severe downturns, then re-entering when asset prices have either fallen further or recovered.